MonoMethyl auristatin E/MMAE CAS:474645-27-7

• Post Date:

  Aug 03,2017

• Expiry Date:

  Aug 03,2018

• Detailed Description:

  Cas No. :474645-27-7 Quantity: 10mgFCL
  Price:145 USD FCL
  Payment Method: MoneyGram,Western Union，T/T
  MonoMethyl auristatin E
  MonoMethyl auristatin E;MMAE;Vedotin;MonoMethyl auristatin E(MMAE, vedotin);HM-297C-22;MonoMethyl auristatin E (MMAE);N-Methyl-L-valyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide;N-Methyl-L-valyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide Monomethyl
  CAS:474645-27-7
  MF:C39H67N5O7
  MW:717.97858
  
  A Brief Introduction of MMAE(Monomethyl Auristatin E, Vedotin)
  What's MMAE?
  Monomethyl auristatin E (abbr. MMAE, commercial name as Vedotin) is a synthetic antineoplastic agent. It cannot be used as a drug itself due to its high toxicity, normally it is linked to a monoclonal antibody (MAB) which directs it to the cancer cells.
  
  Structure of MMAE:
  Please refer to: MMAE | Monomethyl Auristatin E
  MMAE is actually desmethyl-auristatin E; that is, the N-terminal amino group has only one methyl substituent instead of two as in auristatin E itself.
  
  Toxicity of MMAE:
  IC50 of proliferation/viability of tumor cell lines are in the range of 10-7-10-10 M for MMAF/ MMAE auristatin derivatives.
  
  MMAE mechanism of action:
  MMAE inhibits cell division by blocking the polymerisation of tubulin as antimitotic agent in ADCs(Antibody Drug Conjugates).
  
  FDA approved ADCs drugs with MMAE:
  Adcetris (brentuximab vedotin) is an ADC comprised of a chimeric anti-CD30 antibody (cAC10) conjugated through interchain disulfide bonds to monomethyl auristatin E (MMAE) via a valine-citrulline dipeptide cleavable linker, with
  an average DAR of 4.The FDA approval of Adcetris (brentuximab vedotin, Seattle Genetics) in 2011. Adcetris is an antibody-drug conjugate (ADC) directed to the protein CD30, which is expressed in classical Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL).
  
  Commercial Availability of MMAE:
  MMAE is obtained from total synthesis and now available in the market. ALB Technology Limited is a professional ADCs drugs and linkers supplier. ALB Technology Limited provides ADCs products include

• CAS Registry Number:

  474645-27-7

• Synonyms:

  ;MMAE;

• Company:

  Wuhan Deme chem Biotechnology Co., Ltd     [ China ]        

• Contact:

  celia

• Tel:

  +8618942921723

• Fax:

  +86-027-50458986

• Email:

  wzh@dmksw.xin